202197-31-7

Basic information

• Product Name: 5-Amino-1-(3-fluorobenzyl)indazole
• Synonyms: 5-Amino-1-(3-fluorobenzyl)indazole;1-(3-fluorobenzyl)-1H-indazol-5-aMine;1-(3-Fluoro-benzyl)-1H-indazol-5-ylamine
• CAS NO: 202197-31-7
• Molecular Formula: C₁₄H₁₂FN₃
• Molecular Weight: 241.27
• Product Categories: API intermediates
• Mol File: 202197-31-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 438.1°C at 760 mmHg
• Flash Point: 218.7°C
• Appearance: /
• Density: 1.28g/cm³
• Vapor Pressure: 7.11E-08mmHg at 25°C
• Refractive Index: 1.647
• CAS DataBase Reference: 5-Amino-1-(3-fluorobenzyl)indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1-(3-fluorobenzyl)indazole(202197-31-7)
• EPA Substance Registry System: 5-Amino-1-(3-fluorobenzyl)indazole(202197-31-7)

Safety Data

• Hazardous Substances Data: 202197-31-7(Hazardous Substances Data)

Usage

General Description

5-Amino-1-(3-fluorobenzyl)indazole is a chemical compound with the molecular formula C15H12N3F. It is a derivative of indazole, a heterocyclic aromatic organic compound. This particular compound contains a substituent group of 5-amino-1-(3-fluorobenzyl), which is attached to the indazole core structure. It is commonly used in research and pharmaceutical applications, particularly in the development of pharmaceutical drugs and as a biochemical tool for studying various biological processes. 5-Amino-1-(3-fluorobenzyl)indazole may have potential therapeutic properties, and its synthesis and properties are the subject of ongoing scientific study.

InChI:InChI=1/C14H12FN3/c15-12-3-1-2-10(6-12)9-18-14-5-4-13(16)7-11(14)8-17-18/h1-8H,9,16H2

Upstream product

• 456-42-8 m-fluorobenzyl chloride 
• 5401-94-5 5-nitroindazole 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 884874-01-5 2-(3-fluorobenzyl)-5-nitro-2H-indazole 
• 529508-58-5 1-(3-fluorobenzyl)-5-nitro-1H-carbazole 

Downstream Products

• 697299-99-3 [1-(3-fluoro-benzyl)-1H-indazol-5-yl]-(6-iodo-quinazolin-4-yl)-amine hydrochloride 
• 897025-61-5 N⁴-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxyquinazoline-4,6-diamine 
• 1353644-76-4 C₃₀H₂₃FN₆O₃ 
• 1353644-68-4 (3aR,6aR)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3 ,4-b]pyrrole-5(1 H)-carboxamide 
• 1353644-75-3 N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxy-6-nitroquinazolin-4-amine 
• 231278-79-8 N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-6-iodoquinazolin-4-amine 
• 529509-61-3 {4-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-yl}-methanol 
• 529509-71-5 4-{4-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy}-piperidine-1-carboxylic acid tert-butyl ester 
• 529508-59-6 [1-(3-fluoro-benzyl)-1H-indazol-5-yl]-(5-phenylsulfanylmethyl-pyrrolo[2,1-f][1,2,4]triazin-4-yl)-amine 
• 230955-59-6 4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)quinazolin-6-yl acetate 

Relevant articles and documents

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

QUINAZOLINE COMPOUNDS

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.